INBX vs. MRUS, FTSV, RVMD, EXEL, HALO, CRSP, KRYS, IBRX, IMVT, and SWTX
Should you be buying Inhibrx stock or one of its competitors? The main competitors of Inhibrx include Merus (MRUS), Forty Seven (FTSV), Revolution Medicines (RVMD), Exelixis (EXEL), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), Krystal Biotech (KRYS), ImmunityBio (IBRX), Immunovant (IMVT), and SpringWorks Therapeutics (SWTX). These companies are all part of the "medical" sector.
Merus (NASDAQ:MRUS) and Inhibrx (NASDAQ:INBX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, community ranking, earnings, dividends, analyst recommendations, valuation and profitability.
Merus has higher revenue and earnings than Inhibrx. Merus is trading at a lower price-to-earnings ratio than Inhibrx, indicating that it is currently the more affordable of the two stocks.
96.1% of Merus shares are held by institutional investors. Comparatively, 82.5% of Inhibrx shares are held by institutional investors. 4.6% of Merus shares are held by company insiders. Comparatively, 25.8% of Inhibrx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Merus received 299 more outperform votes than Inhibrx when rated by MarketBeat users. Likewise, 65.61% of users gave Merus an outperform vote while only 60.78% of users gave Inhibrx an outperform vote.
Merus has a net margin of -390.36% compared to Merus' net margin of -13,408.95%. Inhibrx's return on equity of -44.13% beat Merus' return on equity.
Merus currently has a consensus target price of $63.80, suggesting a potential upside of 16.27%. Inhibrx has a consensus target price of $27.00, suggesting a potential downside of 21.40%. Given Inhibrx's stronger consensus rating and higher probable upside, research analysts clearly believe Merus is more favorable than Inhibrx.
Merus has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, Inhibrx has a beta of 2.87, suggesting that its stock price is 187% more volatile than the S&P 500.
In the previous week, Merus had 30 more articles in the media than Inhibrx. MarketBeat recorded 35 mentions for Merus and 5 mentions for Inhibrx. Merus' average media sentiment score of 0.95 beat Inhibrx's score of 0.34 indicating that Inhibrx is being referred to more favorably in the news media.
Summary
Merus beats Inhibrx on 13 of the 18 factors compared between the two stocks.
Get Inhibrx News Delivered to You Automatically
Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
